Ananya Kabi1, Ankita Kabi2, Aroop Mohanty3* and Ambika Prasad Mohanty4
1MBBS Student, Siksha ‘O’ Anusandhan Medical College, Bhubaneswar, Odisha, India
2Assistant Professor, Department of Emergency Medicine, AIIMS Rishikesh, Uttarakhand, India
3Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India
4Principal, Kalinga Institute of Medical Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha, India
*Corresponding Author: Aroop Mohanty, Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India.
Received: January 27, 2022 Published: January 31, 2022
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first seen in Wuhan, China in December 2019. At the beginning of the pandemic, there was no drug which could be validated to be used to fight this deadly virus, but two years down the line, the armenaterium of drugs comprises of hydroxychloroquine, antivirals alone or in combination, antibiotics like azithromycin and doxycycline and low dose corticosteroids, either oral or intravenous. On the other hand, monoclonal antibodies have also played a significant role and have proved to be very effective in some cases. Here the authors have attempted to summate the role of new monoclonal antibodies and their effectiveness keeping in mind the discovery of the new variants of COVID-19.
Keywords: COVID-19; Monoclonal antibodies;
Citation: Aroop Mohanty., et al. “Monoclonal Antibodies In Covid-19: A Brief Insight". Acta Scientific Pharmacology 3.2 (2022): 14-17.
Copyright: © 2022 Aroop Mohanty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.